Monthly Archives: August 2017

http://www.lslog.com/tick-saliva-based-drug-could-lower-heart-disease-risk-in-hiv-patients/Tick saliva-based drug could lower heart disease risk in HIV patients

Tick saliva-based drug could lower heart disease risk in HIV patients

Tick saliva-based drug could lower heart disease risk in HIV patients HIV treatments have made enormous strides in recent decades, but patients—even those on antiretroviral drugs—have a higher risk of […]

http://www.lslog.com/stada-close-to-naming-pharma-veteran-albrecht-as-new-ceo-report/Stada close to naming pharma veteran Albrecht as new CEO: report

Stada close to naming pharma veteran Albrecht as new CEO: report

Stada close to naming pharma veteran Albrecht as new CEO: report Hoping to land on its feet after a tough year and a long-time-coming buyout, Stada is nearly ready to […]

http://www.lslog.com/at-475000-is-novartis-kymriah-a-bargain-or-another-example-of-skyrocketing-prices/At $475,000, is Novartis' Kymriah a bargain—or another example of skyrocketing prices?

At $475,000, is Novartis' Kymriah a bargain—or another example of skyrocketing prices?

At 5,000, is Novartis’ Kymriah a bargain—or another example of skyrocketing prices? Novartis won its FDA approval for CAR-T drug Kymriah on Wednesday, but questions about pricing, access and more […]

http://www.lslog.com/daiichi-axes-650m-pain-pact-7-months-after-fda-setback/Daiichi axes $650M pain pact 7 months after FDA setback

Daiichi axes $650M pain pact 7 months after FDA setback

Daiichi axes 0M pain pact 7 months after FDA setback Daiichi Sankyo has cut and run from its $650 million pain alliance with Charleston Laboratories. The decision comes seven months […]

http://www.lslog.com/hit-and-run-gene-therapy-nanoparticles-could-enhance-car-t-treatments/‘Hit-and-run’ gene therapy nanoparticles could enhance CAR-T treatments

‘Hit-and-run’ gene therapy nanoparticles could enhance CAR-T treatments

‘Hit-and-run’ gene therapy nanoparticles could enhance CAR-T treatments Personalized cancer treatments known as CAR-T cells have dominated the headlines lately, but they are labor-intensive and expensive to make, and they […]

http://www.lslog.com/the-medicines-co-nets-400m-nod-for-uti-antibacterial-treatment/The Medicines Co. nets $400M nod for UTI antibacterial treatment

The Medicines Co. nets $400M nod for UTI antibacterial treatment

The Medicines Co. nets 0M nod for UTI antibacterial treatment Doctors treating patients with complicated urinary tract infections will soon have a new tool in their arsenal with the FDA’s […]

http://www.lslog.com/novartis-crosses-fda-finish-line-with-monumental-car-t-leukemia-approval/Novartis crosses FDA finish line with monumental CAR-T leukemia approval

Novartis crosses FDA finish line with monumental CAR-T leukemia approval

Novartis crosses FDA finish line with monumental CAR-T leukemia approval In a historic day for cancer treatment and the larger biopharma industry, Novartis notched an FDA approval for its CAR-T […]

http://www.lslog.com/stealthy-torque-powers-through-with-21m-raise/Stealthy Torque powers through with $21M raise

Stealthy Torque powers through with $21M raise

Stealthy Torque powers through with M raise Flagship Pioneering’s quiet oncology upstart Torque Therapeutics has filed a $21 million raise as it lands in Kendall Square. Source: FierceMedicalDevices News Stealthy […]

http://www.lslog.com/fda-targets-rogue-clinic-using-sanofis-smallpox-vaccine-in-unapproved-cancer-therapy/FDA targets rogue clinic using Sanofi's smallpox vaccine in unapproved cancer therapy

FDA targets rogue clinic using Sanofi's smallpox vaccine in unapproved cancer therapy

FDA targets rogue clinic using Sanofi’s smallpox vaccine in unapproved cancer therapy As part of a crackdown on stem cell treatment centers, the FDA seized a controlled smallpox vaccine from […]

http://www.lslog.com/allergan-heads-to-federal-court-to-defend-restasis-against-early-generic-rivals/Allergan heads to federal court to defend Restasis against early generic rivals

Allergan heads to federal court to defend Restasis against early generic rivals

Allergan heads to federal court to defend Restasis against early generic rivals In defense of a top seller, Allergan is squaring off against a cadre of generics companies in Texas […]